Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
Status:
Terminated
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat
certain hematologic malignancies not responding to standard treatment.